Hyperphosphatemia

Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased serum phosphorous in patients with chronic kidney disease on dialysis, according to a press release from Ardelyx Inc.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Kevin Martin, MD, professor of medicine and director of the division of nephrology at Saint Louis University School of Medicine, about the challenges of managing hyperphosphatemia, prevention measures to recommend to patients at high risk for developing the condition, unmet needs in hyperphosphatemia management and more.